Merck & Co Inc
NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024
MRK Articles
Short sellers appear to be increasing their bets against some of the key dividend stocks we track, judging by the October 15 settlement date for the short interest versus the September 28 settlement...
Published:
Last Updated:
It was twenty-five years ago today that the 1987 stock market crash came. Fortunes were lost on that day, but fortunes were also made in the aftermath. The NYSE was said to be capable of trading...
Published:
Last Updated:
The coming fiscal cliff represents a huge hurdle for America. Government and private sector forecasters have warned that the expiration of tax cuts, along with hundreds of billions of dollars in...
Published:
Last Updated:
The fiscal cliff has been described as a potential disaster for the finances of individuals and corporations alike. If Congress and the White House do not reach an agreement on the budget and tax...
Published:
Short sellers are still active in the high-dividend names out there. Apparently many are under the impression that the dividend bubble is worth betting against. Still, it takes keen conviction to...
Published:
Last Updated:
Short sellers appear to be increasing their bets against some of the key dividend stocks we track each and every day, judging by the August 15 settlement date for the short interest versus the July...
Published:
Last Updated:
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Friday morning. Abercrombie & Fitch Co. (NYSE: ANF) maintained...
Published:
Last Updated:
U.S. stocks are poised to open higher as investors await the first reading on second-quarter U.S. GDP, and after encouraging remarks from Europe’s central bank about supporting the euro. Economists...
Published:
The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do whatever it takes to preserve the euro” (our coverage here)....
Published:
Last Updated:
GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of HIV infection in adults. While Gilead has...
Published:
Last Updated:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday. There are many reports this morning! ADTRAN Inc. (NASDAQ: ADTN) Cut to...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated: